1,076 results
Page 4 of 54
6-K
EX-99.1
wn9cwadw7at5k
24 Apr 23
Current report (foreign)
9:55am
6-K
EX-99.1
c2rmwej 03e4d213zbz
11 Apr 23
Current report (foreign)
1:02pm
SC TO-T/A
EX-99
pj59518cd9f5gbv5g8y
10 Apr 23
Third party tender offer statement (amended)
4:38pm
S-8
p4fpq5i8c9pz93jjo
30 Mar 23
Registration of securities for employees
1:36pm
6-K
EX-99.3
cn9j43rg
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.1
r1xqc9acrr5zypcz3kij
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.2
0p83uwenpuothlf
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.1
vjxf1f
2 Dec 22
Positive Phase II/III study results support acoziborole’s potential in treatment for deadly disease
10:40am
6-K
EX-99.1
qgzph2aqz26g003zk 6w
21 Nov 22
European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
10:05am
6-K
EX-99.1
ylta 6pna
15 Nov 22
Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
3:01pm
6-K
EX-99.2
ew9oeib
15 Nov 22
Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
3:01pm
6-K
EX-99.1
95fykdhfs38b5u1e3
10 Nov 22
European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
2:00pm
6-K
EX-99.1
j9piim7b3ixnx
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.1
bglwrc65
17 Oct 22
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
1:35pm
6-K
EX-99.1
dx6jzvld mrqv
3 Oct 22
Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
11:24am
6-K
EX-99.1
vm30bye nv6u5
22 Sep 22
CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
9:49am
6-K
EX-99.2
5ygjub8bk 1n0e3l
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.3
8suz9ght03mvoaq1
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.1
n8daz rre
2 Sep 22
Current report (foreign)
9:44am
6-K
EX-99.2
mufkjb9cc wqh7up
2 Sep 22
Current report (foreign)
9:44am